Virogates A/s · OMXCOP:VIRO
Virogates A/s — Q1-Q3 2021 Earnings Presentation
22 slides from Virogates A/s's earnings presentation, Nov 15, 2021
Slide 1: ViroGates A/S Interim Q1-Q3 Presentation
1 ViroGates A/S Interim Q1-Q3 Presentation November 2021
Slide 2: Forward-looking statements
2 Forward-looking statements Certain information set forth and given in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements
Slide 3: ViroGates is an international medical technology company developing and marketing blood test products
3 ViroGates is an international medical technology company developing and marketing blood test products Founded in 2001 Headquarter in Birkerød, Denmark 14 Initial public We improve patient outcomes employees offering in by suPARcharging triage for clinicians 2018
Slide 4: suPAR
4 We measure suPAR through blood tests – an inflammatory biomarker that predicts negative patient outcomes suPAR (soluble urokinase Plasminogen Activator Receptor) suPAR is a naturally occurring protein in human blood suPAR reflects the immune system’s activation level suPAR predicts negative patien
Slide 5: suPAR is measured at emergency departments to assist clinicians with making better decisions
5 suPAR is measured at emergency departments to assist clinicians with making better decisions about discharges and hospitalizations General Practitioner Ambulance Personal walk in <4 ng/ml >6 ng/ml Low risk of negative High risk of negative outcomes outcomes – supports discharge Emergency – support
Slide 6: We suPARcharge triage at the emergency department
6 We suPARcharge triage at the emergency department revealing more low-risk patients and slightly more high-risk patients Triage 5% 57% 39% without suPAR Up to ~22% reduction in hospital admissions* Triage 9% 39% 52% with suPAR High risk patients Moderate risk patients Low risk patients Note: Triage
Slide 7: Using suPAR in clinical routine can improve patient outcomes, reduce healthcare costs
7 Using suPAR in clinical routine can improve patient outcomes, reduce healthcare costs and empower clinical staff “The addition of suPAR to National Early Warning 34% Score significantly improved risk prediction of more patients in the both low- and high-risk acute medical patients” low risk catego
Slide 8: suPAR has the highest prognostic value compared to complementary biomarkers and risk scoring systems
8 suPAR has the highest prognostic value compared to complementary biomarkers and risk scoring systems Prognostic Consistently highest prognostic value for negative Complementary patient outcomes (e.g. mortality) biomarkers/systems Non-specific CRP Works across all types of potentially lethal diseas
Slide 9: More than 700 peer-reviewed suPAR studies in leading medical journals
9 More than 700 peer-reviewed suPAR studies in leading medical journals – the vast majority conducted using suPARnostic® Number of accumulated published suPAR studies # 726 627 377 206 106 148 2000 2005 2010 2015 2020 2021 PubMed.org
Slide 10: Phase 3 trial of suPAR-guided anakinra treatment in COVID-19 patients published in Nature Medicine
10 In September, the results from the phase 3 trial of suPAR-guided anakinra treatment in COVID-19 patients was published in Nature Medicine 64% improved overall clinical outcome for COVID-19 patients • Significant prevention of death • Significant prevention of progression to severe respiratory fai
Slide 11: ViroGates produces and sells three prognostic biomarker products under the brand suPARnostic
11 ViroGates produces and sells three prognostic biomarker products under the brand suPARnostic® for the healthcare sector in Europe suPARnostic® Products TurbiLatex ~20 EUR per test for end-users Automated clinical use (Turbidimetric) +80% gross margin Quick ELISA Triage Recurring sales (ViroGates
Slide 12: The suPARnostic TurbiLatex product fits into existing hospital workflows
12 The suPARnostic® TurbiLatex product fits into existing hospital workflows and has been validated on the most popular biochemistry analyzers Easy to use Fits directly into existing work flow and turnaround time in clinical TurbiLatex biochemistry with no additional samples or work flow steps neede
Slide 13: ViroGates' current strategic focus is on Acute Care in Europe
13 ViroGates’ current strategic focus is on Acute Care in Europe through direct sales representatives and distributors (indirect sales) Direct sales Strategic priority High level of control Max capture of value chain Indirect sales Extension of reach Controlled from HQ Value sharing with distributor
Slide 14: ViroGates has a global ~€1 billion market opportunity in Acute Care
14 ViroGates has a global ~€1 billion market opportunity in Acute Care – healthcare savings potential varies across markets Global ViroGates market opportunity in Acute Care Healthcare savings potential in Acute Care (example markets)* Million EUR Million EUR Net healthcare savings Cost of using suP
Slide 15: We expect to launch a new fingerprick product in the first half of 2022
15 We expect to launch a new fingerprick product in the first half of 2022 – the suPARnostic® POC+ +3 billion EUR annual market opportunity in Europe General • Health screens and Practitioners regular visits at the GP offices Prototype Small point-of-care device +1 billion EUR annual market opportun
Slide 16: ViroGates has a strong IP base with freedom to operate in clinical settings
16 ViroGates has a strong IP base with freedom to operate in clinical settings – and no bio-equivalent competing products research settings either Patent family ID Main claim Expiry WO2001/038871 HIV prognostication 2020 Prognostication based on various WO2002/095411 2022 bacterial pathogens Prognos
Slide 17: ViroGates has an experienced management team and board
17 ViroGates has an experienced management team and board Management Team Non-Executive Board Jakob Knudsen, CEO, LL.M & MBA Dr. Lars Kongsbak (Chairman) • +15 years operational experience in life science • +25 years operational experience in • CEO ViroGates A/S since 2011, CCO and CFO Egalet Inc. l
Slide 18: Interim Report - Q1-Q3, 2021
18 Interim Report - Q1-Q3, 2021 November 2021
Slide 19: Revenue increased by 66% in Q1-Q3, 2021, compared to last year
19 Revenue increased by 66% in Q1-Q3, 2021, compared to last year – Q3 revenue was lower than recent quarters due to hospital vacation periods Financial results in Q1-Q3, 2021 (Q1-Q3, 2020 results in brackets) TDKK +66% • Revenue increased by 66% to TDKK 5,063 (TDKK 3,055) Revenue 3,055 5,063 • Oper
Slide 20: Financial highlights (continued)
20 Financial highlights (continued) Revenue by product Revenue by geographic area DKKm, % of total DKKm, % of total TurbiLatex ELISA Europe Other regions Quick Triage Other North America 3.1 5.1 3.1 5.1 29% 46% 69% 23% 77% 24% 46% 18% 29% 20% 13% 1% 1% 3% Q1-Q3, 2020 Q1-Q3, 2021 Q1-Q3, 2020 Q1-Q3, 2
Slide 21: What should investors look out for in Q4 and beyond?
21 What should investors look out for in Q4 and beyond? COVID-19 Clinical routine suPARnostic® EMA evaluation customers POC+ Potential future Potential future Expected launch of the announcements on the announcements of new suPARnostic® POC+ in the first regulatory process with EMA clinical routine
Slide 22: Thank you for your attention!
22 Thank you for your attention! Jakob Knudsen +45 2226 1355 jk@virogates.com Mark Christian Hvidberg da Silva +45 6163 5600 mds@virogates.com